Artal Group S.A.
Q4 2013 13F-HR Holdings
Net value change ($000)
—
New positions
35
Sold out positions
0
Turnover %
100.0%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to previous filing: —
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| WTW | 946,708 | — |
| LEXICON GENETICS INC US$0.001 Common Stock | 456,064 | — |
| FURIEX PHARMA INC | 36,584 | — |
| AUXILIUM PHARMACEUTICALS | 31,095 | — |
| BMRN | 28,140 | — |
| ImmunoGen, Inc. | 24,206 | — |
| Acorda Therapeutics, Inc. | 20,440 | — |
| NKTR | 18,160 | — |
| PHARMACYCLICS INC | 17,454 | — |
| AMGN | 17,112 | — |
Top Reduces (Value $000, Stocks/ETFs)
| — |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
1,058,912
(38.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|